Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly
S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or
IV platinum resistant ovarian cancer or primary peritoneal carcinoma.